SECURITIES AND EXCHANGE COMMISSION
Washington, D. C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report: June 11, 1996
Seafield Capital Corporation
------------------------------------------------------
(Exact name of registrant as specified in its charter)
Missouri 0-16946 43-1039532
-----------------------------------------------------------------
(State of other (Commission File Number) (IRS Employer
jurisdiction of Identification
incorporation) Number)
2600 Grand Ave. Suite 500
P. O. Box 410949
Kansas City, MO 64141
-----------------------------------------------------------------
(Address of principal executive offices) (Zip code)
(816) 842-7000
-----------------------------------------------------------------
(Registrant's telephone number, including area code)
Item 5. Other Events
On June 4, 1996, the Registrant announced that its 56% owned subsidiary,
Response Oncology, Inc. (Response), has executed a Loan Agreement with
NationsBank of Tennessee, N.A. as lead bank providing Response with a $27.5
million unsecured credit facility for acquisitions and working capital. Union
Planters National Bank is a participant in the financing. The portion of the
facility dedicated to acquisitions, amounting to $22 million, matures May 31,
1998. The working capital portion, amounting to $5.5 million, matures May 30,
1997, subject to a one year renewal at the option of Response. Both portions
of the credit facility bear interest at variable interest rates that are tied
to the London Interbank Offered Rate (LIBOR).
The Registrant also announced that Response has executed two additional letters
of intent to enter into practice affiliation transactions and practice
management relationships with two medical oncology practices consisting of five
medical oncologists in the state of Florida. The letters of intent contemplate
closing dates on or before September 1, 1996. If consummated, these
transactions will increase Response's practice management relationships to 22
medical oncologists.
On June 4, 1996, the Registrant announced that its 82% owned subsidiary,
LabOne, Inc. (LabOne), was notified by Epitope, Inc. that the Food and Drug
Administration (FDA) had approved the OraSure(registered trademark) HIV-1
Western Blot Test. LabOne plans to include the oral fluid confirmation test in
its standard oral fluid testing services, as soon as the confirmatory test is
available for purchase. LabOne views this approval as an important step in the
expansion of oral fluid testing for risk assessment purposes.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized officer.
Seafield Capital Corporation
Date: June 11, 1996 By: /s/ Steven K. Fitzwater
---------------------------
Steven K. Fitzwater
Vice President, Chief Accounting
Officer and Secretary
